In a ruling that is sure to fan controversy, a Food and Drug Administration advisory committee voted 6-0 Wednesday that two key studies on which it made its accelerated approval of the drug Avastin for breast cancer use conditional showed that it is not effective in treating the disease, the Wall Street Journal reports. The panel also unanimously agreed that the drug had not been shown to have clinical benefits for breast cancer patients. The votes were a setback for the company that makes Avastin, Genentech, and also for patients who insist the drug has helped them in their struggles with breast cancer. (Previous studies indicated that the drug delayed tumor growth by about five-and-a-half months and improved the quality of life for the patients who used it.) Still unresolved is whether the panel will vote to retract its approval of the drug for breast cancer patients while further research is undertaken.